GSK will invest up to £50 million in the new project, which could inform future development of cancer vaccines.

Alphabet also remains a popular pick among hedge fund managers. According to Insider Monkey data, 202 hedge fund investors ...

LONDON - GlaxoSmithKline PLC (LSE/NYSE: NYSE:GSK) announced today that the European Medicines Agency (EMA) has begun ...

The company said under a collaboration with the university it would invest £50m over three years to find out whether cancers could be prevented from developing with jabs.

Jemperli (dostarlimab) in combination with chemotherapy (carboplatin and paclitaxel) for first-line treatment of adult ...

Ab&B Bio-Tech has joined the stacked roster of drug developers queuing up to go public in Hong Kong, filing the paperwork for ...

We recently published a list of 12 Undervalued Defensive Stocks for 2025. In this article, we are going to take a look at ...

GSK Plc’s Chief Executive Officer Emma Walmsley is looking to do more deals as the British drugmaker doubles down on its ...

IDRx’s lead candidate IDRX-42 is being investigated in a Phase I/IIb trial in patients with advanced gastrointestinal stromal ...

The British pharma giant announced plans to acquire IDRx, a Plymouth-based biotech working on precision treatments for ...

And while Wood said the pharma still isn’t interested in joining the overcrowded obesity landscape, GSK is considering ways ...

We recently compiled a list of the 12 Cheapest Stocks with Biggest Upside Potential. In this article, we are going to take a ...